Ubs Group Ag Centessa Pharmaceuticals PLC Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Centessa Pharmaceuticals PLC stock. As of the latest transaction made, Ubs Group Ag holds 5,007 shares of CNTA stock, worth $84,618. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,007

Previous 2,809 78.25%

Holding current value

$84,618

Previous $25,000 220.0%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$8.58 - $16.99 $18,858 - $37,344	2,198 Added 78.25%	5,007 $80,000
Q2 2024 Aug 13, 2024	BUY	$8.04 - $11.87 $7,485 - $11,050	931 Added 49.57%	2,809 $25,000
Q1 2024 May 13, 2024	BUY	$6.73 - $12.2 $1,985 - $3,599	295 Added 18.64%	1,878 $21,000
Q4 2023 Feb 09, 2024	SELL	$5.52 - $8.03 $5,812 - $8,455	-1,053 Reduced 39.95%	1,583 $12,000
Q3 2023 Nov 09, 2023	BUY	$6.01 - $8.24 $3,113 - $4,268	518 Added 24.46%	2,636 $17,000
Q2 2023 Aug 11, 2023	SELL	$3.68 - $6.9 $11,205 - $21,010	-3,045 Reduced 58.98%	2,118 $13,000
Q1 2023 May 12, 2023	BUY	$3.03 - $4.0 $7,808 - $10,308	2,577 Added 99.65%	5,163 $19,000
Q4 2022 Feb 08, 2023	BUY	$3.05 - $4.19 $3,135 - $4,307	1,028 Added 65.98%	2,586 $8,000
Q3 2022 Nov 10, 2022	BUY	$3.8 - $5.91 $5,920 - $9,207	1,558 New	1,558 $6,000
Q1 2022 May 16, 2022	SELL	$7.45 - $11.59 $3,695 - $5,748	-496 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$10.99 - $17.54 $3,022 - $4,823	275 Added 124.43%	496 $6,000
Q3 2021 Nov 15, 2021	SELL	$16.7 - $23.11 $7,631 - $10,561	-457 Reduced 67.4%	221 $4,000
Q2 2021 Aug 13, 2021	BUY	$21.71 - $25.66 $14,719 - $17,397	678 New	678 $15,000

Others Institutions Holding CNTA

# of Institutions

108

Shares Held

118M

Call Options Held

5.9K

Put Options Held

53K

View Full List

About Centessa Pharmaceuticals plc

Ticker CNTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,339,296
Market Cap $1.59B
Description
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; an...

More about CNTA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account